Genetic alterations related to familial alzheimer's...

Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C435S325000, C435S320100, C435S252300, C536S023500, C536S023100

Reexamination Certificate

active

06248555

ABSTRACT:

FIELD OF THE INVENTION
The present invention relates generally to Alzheimer's disease, and more specifically to methods and compositions for use in diagnosis and treatment of Alzheimer's Disease.
BACKGROUND OF THE INVENTION
Alzheimer's disease (AD) is a devastating neurodegenerative progressive disorder, which is the predominant cause of dementia in people over 65 years of age. The prevalence of AD is estimated to be as high as 18.7% among 75-84 year-olds and 47.2% among the ≧85 year age groups, affecting a significant portion of the population in most countries of the world.
Clinical symptoms of the disease typically begin with subtle short term memory problems. As the disease progresses, difficulty with memory, language, and orientation worsen to the point of interfering with the ability of the person to function independently. Other symptoms, which are variable, include myoclonus and seizures. Duration of AD from the first symptoms of memory loss until death is 10 years on average, but may range from 6-8 years to more than 20 years. AD always results in death, often from respiratory-related illness.
The pathology in AD is confined exclusively to the central nervous system (CNS). The AD brain is characterized by the presence of amyloid deposits and neurofibrillary tangles (NFT).
Amyloid deposits are found associated with the vascular system of the CNS and as focal deposits in the parenchyma. The major molecular component of an amyloid deposit is a highly hydrophobic peptide called the A&bgr; peptide. This peptide aggregates into filaments in an anti-&bgr;-pleated sheet structure resulting in the birefringent nature of the AD amyloid. Although A&bgr; is the major component of AD amyloid, other proteins have also found associated with the amyloid, e.g., &agr;-1-anti-chymotrypsin (Abraham, et al.,
Cell
52:487-501 (1988)), cathepsin D (Cataldo et al.,
Brain Res
. 513:181-192 (1990)), non-amyloid component protein (Ueda et al.,
Proc. Natl. Acad. Sci. USA
90:11282-11286 (1993)), apolipoprotein E (apoE) (Namba et al.,
Brain Res
. 541:163-166 (1991); Wisniewski & Frangione,
Neurosci. Lett
. 135:235-238 (1992); Strittmatter et al.,
Proc. Natl. Acad. Sci. USA
90:1977-1981 (1993)), apolipoprotein J (Choi-Mura et al.,
Acta Neuropathol
. 83:260-264 (1992); McGeer et al.,
Brain Res
. 579:337-341 (1992)), heat shock protein 70 (Hamos et al.,
Neurology
41:345-350 (1991)), complement components (McGeer & Rogers,
Neurology
43:447-449 (1992)), &agr;
2
-macroglobin (Strauss et al.,
Lab. Invest
. 66:223-230 (1992)), interleukin-6 (Strauss et al.,
Lab. Invest
. 66:223-230 (1992)), proteoglycans (Snow et al.,
Lab. Invest
. 58:454-458 (1987)), and serum amyloid P (Coria et al.,
Lab. Invest
. 58:454-458 (1988)).
Plaques are often surrounded by astrocytes and activated microglial cells expressing immune-related proteins, such as the MHC class II glycoproteins HLA-DR, HLA-DP, and HLA-DQ, as well as MHC class I glycoproteins, interleukin-2 (IL-2) receptors, and IL-1. Also surrounding many plaques are dystrophic neurites, which are nerve endings containing abnormal filamentous structures.
The characteristic Alzheimer's NFTs consist of abnormal filaments bundled together in neuronal cell bodies. “Ghost” NFTs are also observed in AD brains, which presumably mark the location of dead neurons. Other neuropathological features include granulovacular changes, neuronal loss, gliosis and the variable presence of Lewy bodies.
The destructive process of the disease is evident on a gross level in the AD brain to the extent that in late-stage AD, ventricular enlargement and shrinkage of the brain can be observed by magnetic resonance imaging. The cells remaining at autopsy, however, are grossly different from those of a normal brain, characterized by extensive gliosis and neuronal loss. Neurons which were possibly involved in initiating events, are absent; and other cell types, such as the activated microglial cells and astrocytes, have gene expression patterns not observed in the normal brain. Thus, the amyloid plaque structures and NFTs observed at autopsy are most likely the end-products of a lengthy disease process, far removed from the initiating events of AD.
Accordingly, attempts to use biochemical methods to identify key proteins and genes in the initiating steps of the disease are hampered by the fact that it is not possible to actually observe these critical initiating events. Rather, biochemical dissection of the AD brain at autopsy is akin to molecular archeology, attempting to reconstruct the pathogenic pathway by comparing the normal brain to the end-stage disease brain.
Substantial evidence has suggested that inherited genetic defects are involved in AD. Numerous kindreds have been described in the literature as having early-onset AD (defined as onset before age 65). Bird et al.,
Ann. Neurol
. 23:25-31 (1988); Bird et al.,
Ann. Neurol
, 25:12-25 (1989); Cook et al.,
Neurology
29:1402-1412 (1979); Feldman et al.,
Neurology
13:811-824 (1960); Goudsmit,
J. Neurol. Sci
. 49:79 (1981); Heston & White,
Behavior Genet
. 8:315-331 (1978); Martin et al.,
Neurology
41:62-68 (1991); Nee et al.,
Arch. Neurol
. 40:203-208 (1983); van Bogaeert et al.,
Mschr. Psych. Neurol
. 102:249-301 (1940); Wheelan,
Ann. Hum. Genet
. 23:300-309 (1959)). Families with multiple late-onset AD cases have also been described (Bird et al.,
Ann. Neurol
. (1989), supra; Heston & White,
Behavior Genet
. (1978), supra; Pericak-Vance et al.,
Exp. Neurol
. 102:271-279 (1988)). In addition, twin studies have documented that monozygotic twins are more concordant in their AD phenotype than dizygotic twins (Nee et al.,
Neurology
37:359-363 (1987). Also, the families of concordant twins have more secondary cases of AD than families of discordant twins (Rapoport et al.,
Neurology
41:1549-1553 (1991)).
Genetic dissection of AD has been complicated by the complexity and overall accuracy of its diagnosis. Because AD is relatively common in the elderly, clustering of cases in a family may occur by chance, representing possible confounding non-allelic genetic heterogeneity, or etiologic heterogeneity with genetic and non-genetic cases co-existing in the same kindred. In addition, the clinical diagnosis of AD is confounded with other dementing diseases common in the elderly.
Despite these problems, mutations in the amyloid precursor protein (APP) gene on chromosome 21 have been associated with early-onset (<65 years) autosomal dominant AD (Goate et al.,
Nature
349:704 (1991)). Moreover, mutations in two recently identified genes, S182 on chromosome 14 and STM-2 on chromosome 1, which encode presenilin 1 (PS1) and presenilin 2 (PS2), respectively, have also been associated with early-onset autosomal dominant AD (Schellenberg et al.,
Science
258:668 (1992); Sherrington et al.,
Nature
375:754-760 (1995); Levy-Lahad/Wasco et al.,
Science
269:973-977 (1995)).
For late-onset AD, the APOE gene has been identified as a genetic modifying factor (Strittmatter et al.,
Proc. Natl. Acad. Sci. USA
90:1977 (1993); Corder et al.,
Science
261:921 (1993); Corder et al.,
Nat. Genet
. 7:180-184 (1994); Benjamin et al.,
Lancet
344:473 (1994); Smith et al.,
Lancet
344:473-474 (1994)).
However, the known genetic loci for AD do not account for all cases of AD. For example, in late-onset AD approximately half of AD cases do not have the APOE &egr;4 allele found in several other families with high incidence of AD, including the Volga German (VG) kindreds. Brousseau et al.,
Neurology
342 (1994); Kuusisto et al.,
Brit. Med. J
. 309:363 (1994); Tsai et al.,
Am. J. Hum. Genet
. 54:643 (1994); Liddel et al.,
J. Med. Genet
. 31:197 (1994); Cook et al.,
Neurology
(1979), supra; Bird et al.,
Ann. Neurol
. (1988), supra; Bird et al.,
Ann. Neurol
. 25:12 (1989). The known AD loci have been excluded as possible causes of the discrepancy. Schellenberg et al.,
Science
(1992), supra; Lannfelt et al.,
Nat. Genet
. 4:218-219 (1993)); van Duijn et al.,
Am. J Hum. Genet
. 55:714-727 (1994); Schellenb

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Genetic alterations related to familial alzheimer&apos;s... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Genetic alterations related to familial alzheimer&apos;s..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Genetic alterations related to familial alzheimer&apos;s... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2489589

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.